CLOs on the Move

Managed Health Services

www.mhsindiana.com

 
Managed Health Services is a Indianapolis, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Howard County General Hospital

Howard County General Hospital is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Howard County General Hospital is based in Columbia, MD. You can find more information on Howard County General Hospital at www.hcgh.org

EvidenceCare

EvidenceCare is the only decision support tool designed exclusively for clinicians that delivers evidence-based medicine individualized for each patient they treat. Our patent pending technology lowers costs and improves outcomes in a way that benefits patients, providers, payers, and clinics. We provide the evidence, so you can provide the care.

pSivida

pSivida is a leading provider of miniaturized, sustained-release drug delivery products and is continuing the evolution of these systems.

ORCHA

DIGITAL HEALTH. UNLOCKED. Join the journey to transform the worlds health. Healthcare is in the middle of a digital revolution, yet the digital health market is unregulated. As the global leader in providing access to trusted digital health technologi...

Humacyte

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte`s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte`s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA`s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.